Intramedullary mesenchymal stromal cell transplantation in humans: Procedural safety and oncological risk reassessment.
Nonnarath C., Serratrice N.
Narrative Review on Spinal Cord Injury, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Cell Transplant (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42415699
- DOI
- 10.1177/09636897261466805
Abstract (original English)
Intramedullary cellular transplantation within the human spinal cord has historically been regarded as a highly experimental intervention associated with substantial theoretical risk. However, cumulative clinical evidence progressively challenges this perception. Multiple early-phase clinical studies have demonstrated the technical feasibility and procedural tolerability of intramedullary and intralesional cellular delivery in spinal cord injury (SCI), employing heterogeneous cellular products, including bone marrow-derived mononuclear cells, mesenchymal stromal cells (MSCs), and neural stem cells. Despite considerable heterogeneity in cellular composition, dosing strategies, injection volumes, and delivery paradigms, severe injection-related complications remain uncommon. Reported adverse events are predominantly mild and transient, while procedure-induced neurological deterioration has not emerged as a reproducible safety signal. These observations suggest that controlled spinal cellular administration may represent a biologically tolerated intervention rather than an intrinsically destabilizing procedure. Beyond procedural considerations, long-term biological safety remains a central dimension of translational evaluation. While theoretical concerns persist - particularly regarding tumorigenesis, clonal selection, and potential genomic instability associated with ex vivo MSC
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level AMeta-analysisPubMed
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Meta-analysis on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol - Level ASystematic ReviewPubMed
Brain-derived neurotrophic factor (BDNF) as biomarker in stem cell-based therapies of preclinical spinal cord injury models: A systematic review.
Systematic Review on Spinal Cord Injury, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
- 2025
Tissue Cell3 citations - Level ASystematic ReviewEurope PMC
Revolutionizing neural regeneration with smart responsive materials: Current insights and future prospects
Systematic Review on Spinal Cord Injury, published in Bioact Mater (2025) — summary generated from the PubMed abstract.
- 2025
Bioact Mater5 citations - Level ASystematic ReviewEurope PMC
Conductive Nanocomposite Hydrogels for Neural Tissue Engineering: A Systematic Scoping Review of Recent Trends
Systematic Review with a reported sample of 42 on Diabetic Foot, Stroke Research, Spinal Cord Injury, Neuroinflammation, published in Adv Sci (Weinh) (2025) — summary generated from the PubMed abstract.
- 2025
- n = 42
Adv Sci (Weinh)18 citations - Level ASystematic ReviewEurope PMC
Emerging regenerative strategies for spinal cord injury: exosome-derived mechanisms and therapeutic insights
Systematic Review on Spinal Cord Injury, Neuroinflammation, published in Front Neurosci (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurosci